Today's trade is in a mental health biotech company focused on developing psychedelic-assisted therapies — primarily a synthetic form of psilocybin called COMP360 — for difficult-to-treat psychiatric conditions.
After being hit hard in 2025, the group has spent most of the year repairing damage and trying to find its footing while much of the market has gone vertical.
If there is anything more volatile than my PnL, it is often my mental state. It's not something I'm proud of. When I'm winning, I'm often ebullient. When I'm losing, I'm usually pretty sullen. This sucks for me and...
We love our bottoms-up scans here at All Star Charts. We tend to get really creative when making new universes as we want to be sure they will deliver us the best opportunities the market has to...